Cardiac Fibrosis {#S1}
================

The healthy heart is supported by a distinct network of extracellular matrix (ECM) proteins, which function in part to preserve chamber structure and aid in cardiac cell communication ([@B82]; [@B34]). Fibroblasts resident to the heart are primarily responsible for maintaining the ECM, which typically consists of roughly 80 percent type I collagens, 10 percent type III collagens, and a combination of proteoglycans, glycoproteins, and glycosaminoglycans ([@B69]). The cardiac ECM is highly dynamic, and it's homeostasis is preserved through a few mechanisms: a strict balance between protein synthesis and degradation, as well as protein reorganization within the network ([@B82]). However, virtually any injury to the heart will activate fibrosis, or a dysregulated and enhanced growth of the ECM milieu, since the adult heart holds limited capacity for regeneration ([@B57]). For instance, following a myocardial infarction (MI), the severe loss of cardiomyocytes triggers increased matrix production in an effort to replace lost and damaged tissue ([@B35]). Further, other pathologies like pressure overload due to hypertension, volume overload, diabetes, obesity, and even aging can stress any chamber of the heart, therefore leading to fibrotic growth around the vasculature and within the interstitium ([@B3]; [@B35]). Although this matrix growth initially serves as a form of repair, it can quickly become detrimental ([@B35]). An exaggerated production of collagens can result in myocardial stiffening, which disrupts cardiac compliance and ultimately decreases systolic and diastolic function ([@B69]; [@B124]). Importantly, it has recently been shown that severe cardiac fibrosis, especially when accompanied by heart failure (HF) is associated with increased mortality in patients ([@B7]; [@B46]). While there are currently treatment options that help in managing the symptoms of heart disease, there are no effective therapies targeted at controlling pathological fibrosis. Therefore, an in-depth discussion, focusing on the mechanisms that contribute to the genesis of fibrosis is extremely necessary ([@B46]; [@B124]; [@B2]; [@B57]).

In past years, numerous rigorous studies have identified the resident cardiac fibroblast as a crucial cell effector of pathological fibrosis ([@B21]; [@B66]; [@B124]; [@B40]; [@B60]). Due to injury, resident fibroblasts proliferate, and differentiate into mature cardiac myofibroblasts, which, through *de novo* expression of α smooth muscle actin (αSMA) can contract to support wound healing ([@B21]). Activated myofibroblasts also contribute to fibrosis by secreting copious amounts of matrix protein, which then overwhelms the ECM ([@B21]; [@B120]; [@B124]). Due to the hearts cellular complexity, additional sources, including vascular and bone marrow derived cells have been considered for their contribution to myofibroblast differentiation and fibrosis ([@B66]; [@B127]; [@B124]; [@B40]). This review will focus on the leukocyte dependent regulation of fibrosis since it has been well reported that the activation of resident fibroblasts into myofibroblasts is heavily influenced by changes in the myocardial environment ([@B21]; [@B120]). This is important to note, as injury results in damaged cardiomyocytes which incite inflammation and promote a large expansion and infiltration of leukocytes ([@B122]; [@B43], [@B44]; [@B123]). These infiltrating leukocytes occupy spaces near sites of injury, and function through cytokines and growth factors secretions, which contribute to changes in myocardial environment ([@B122], [@B123]). As such, the role of leukocytes in cardiac fibrosis has been a longstanding research focus. Since leukocytes drastically expand in number following injury, and exhibit high cellular plasticity, earlier studies sought to determine if, and to what extent, leukocytes serve as additional cell sources for myofibroblast transdifferentiation ([@B128]; [@B4]). More recent studies have focused on both the direct and indirect roles of distinct leukocyte subsets in cardiac fibrosis. Below, we will examine the current understanding of leukocytes in cardiac biology, focusing on how they may regulate cardiac fibrosis, and examining if they can be targeted to control fibrosis.

Leukocytes in Cardiac Physiology and Pathology {#S2}
==============================================

Any tissue injury leads to inflammation, which engages a collective of white blood cells termed leukocytes ([@B42]; [@B68]). The primary function of leukocytes is to sense and respond to pathogens or damage in order to suppress any additional danger ([@B68]). Leukocytes exist in various subsets, and can be classified as being of either lymphoid or myeloid origin ([@B68]). Their origin and subsequent gene expression profiles are key to their function ([@B42]; [@B68]). All leukocytes initially derive from hematopoietic stem cells, which differentiate into either lymphoid or myeloid progenitors ([@B68]). Lymphoid progenitors give rise to B and T lymphocytes, natural killer cells, and some subsets of dendritic cells ([@B68]). Myeloid progenitors are precursors for megakaryocytes, erythrocytes, granulocytes, and monocytes ([@B68]). Seminal studies in recent years have provided ample evidence for the roles and origins of leukocytes both in the steady-state and injured heart ([@B30]; [@B123]).

Through flow cytometry and single cell RNA sequencing technologies, researchers have established the presence of many leukocyte subsets in the injured and healthy heart, with most of them being macrophages ([@B30]; [@B123]; [@B3]; [@B25]). Further studies using adult mouse hearts have allowed us to gain greater appreciation for the existence and diversity of these cardiac macrophage populations ([@B123]). A minority of cardiac macrophages, expressing chemokine receptor 2 (CCR2), stem from circulating monocyte precursors ([@B30]; [@B10]). However, additional cardiac macrophage subsets have been shown to inhabit the heart early, and persist throughout adulthood via proliferation ([@B30]; [@B10]; [@B25]). Functionally, cardiac macrophages are thought to act as pathogen sensors, but they may also take more active part in myocardial electrical conduction ([@B85]; [@B123]). Interestingly, recent findings suggest an abundance of connexin 43-expressing macrophages in the atrioventricular (AV) node, which exhibit an ability to couple to cardiomyocytes and alter their membrane potential ([@B54]). Other leukocyte populations in the steady-state heart include lymphocytes, dendritic and mast cells ([@B16]; [@B123]). The complete function of these cells is still not entirely understood, however, mast cells have been shown to be stores of preformed cytokines, which may prove beneficial at the onset of injury ([@B38]).

Cardiac fibrosis is a typical feature of ageing and injury, both of which are known to trigger leukocyte expansion and inflammation within the heart ([@B31]; [@B81]; [@B121]; [@B3]). For instance, a plethora of studies have revealed the rapid and continuous innate immune response that follows acute ischemic injuries. Neutrophils and inflammatory monocytes/macrophages infiltrate the myocardium in response to endogenous damage-associated molecular patterns (DAMPs) where they can effectively clear dying cells and regulate inflammation through cytokines, chemokines, and reactive oxygen species ([@B33]). Following this pro-inflammatory phase, additional monocyte subsets (Ly6C^*lo*^) are recruited to promote transition to injury repair through secretion of pro-repair factors ([@B96]; [@B33]). Cluster of differentiation (CD) 11b^+^/CD11c^+^ dendritic cells have also been shown to accumulate in the border zone post-myocardial infarction (MI), peaking around 7 days post-injury ([@B41]). Dendritic cells are thought to aid in preserving left ventricle (LV) function activate T lymphocyte subsets through antigen presenting functions ([@B33]). The role of adaptive immunity in response to ischemic injury is still being uncovered, however, recent studies suggest the involvement of both B and T lymphocytes in cardiac remodeling post-MI ([@B33]). For instance, CD4^+^ T cells have been shown to invade the heart by 7 days post-MI, where they are presumed to modulate LV function ([@B51]). Similarly, B cell volumes expand following MI, reaching a peak around 5--7 days post-injury ([@B141]; [@B143]). Functionally, B cells may contribute to the regulation of inflammatory gene expression post-ischemic injury ([@B143]). The innate and adaptive immune response have also been characterized in ageing and injuries of non-ischemic etiology. For instance, mouse models of advanced ageing, and hypertension through high salt, unilateral nephrectomy, and aldosterone infusion, reveal increased neutrophil and macrophage populations within the heart ([@B55]). The presence of these immune cells is associated with enhanced diastolic dysfunction. Further, pressure overload induced pathology due to transverse aortic constriction (TAC) has also been shown to result in an increased infiltration of leukocytes, both CCR2^+^ macrophages and CD4^+^ T cells ([@B72]; [@B105]). The rise in leukocytes to the heart following these pathophysiological changes has prompted many researchers to question the link between inflammation and fibrosis.

Leukocyte Involvement in Cardiac Fibrosis {#S3}
=========================================

Fibrosis and inflammation are essential physiological processes that follow essentially all cardiac pathologies ([@B123]). During inflammation, leukocytes function to resolve injury and defend the host through several eloquent mechanisms ([@B68]; [@B9]). The existing literature suggests several connections between leukocyte driven inflammation and cardiac fibrosis. Below, we consider the evidence supporting leukocyte dependent regulation of fibrosis with the ultimate goal of highlighting novel targets in the quest for combating detrimental fibrotic remodeling ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}).

###### 

This table lists evidence in support of how each leukocyte class may regulate cardiac fibrosis in distinct pathological contexts.

  **Leukocyte class**     **Pathological context**   **Contribution to fibrosis**
  ----------------------- -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Neutrophils             Ischemia                   5 day post MI, increase in **CD206** and or **Arg-1** expressing neutrophils is associated with decreased myofibroblast transdifferentiation ([@B64]) 7 days post MI, neutrophils express **Fibronectin**, **Gal-3**, **Fibrinogen** which contributes to ECM reorganization ([@B20]) 21 days post MI, loss of **MPO** reduces fibrosis ([@B91]) Post MI, loss of **NGAL** expressing neutrophils may affect dead myocyte phagocytosis and contribute to fibrosis ([@B53])
                          Myocarditis/DCM; Ageing    In chronic myocarditis and ageing decreased neutrophil infiltration and **NETosis**/**NET** formation is associated with reduced fibrosis ([@B87]; [@B136])
  Monocytes/Macrophages   Ischemia                   1--6 weeks post MI, macrophages may transition to fibroblast-like cells, capable of secreting collagen ([@B47]) **IL-10** and **TGFβ** secreting macrophages promote myofibroblasts transdifferentiation ([@B102]) 1 week post ischemia/reperfusion, loss of **MCP-1** is associated with decreased macrophage infiltration and interstitial fibrosis ([@B37]) 4 weeks post MI, **Gata6** expressing pericardial macrophages limit cardiac fibrosis ([@B23])
                          Pressure Overload          Macrophage associated **Gal-3** correlates with increased cardiac fibrosis in hypertensive rats ([@B22]) 8 weeks following uninephrectomy and salty drinking water, loss of macrophage expressed **mineralocorticoid receptor** reduces cardiac collagen content ([@B112])
  Mast Cells              Pressure Overload          Mast cells contribute to **PDGF-A** expression and fibrosis in the heart following TAC ([@B78])
                          DCM                        Mast cells are a large source of **FGF-2**, and found within fibrotic sections of cardiac tissue ([@B15])
  Eosinophils             Myocarditis/DCM            Eosinophil depletion post myocarditis is associated with decreased levels of **MMP-2** and **TIMP-2** ([@B26])
  Dendritic Cells         Ischemia                   Ablation of dendritic cells results in increased **MMP-9** and **MMP-2** activity 3--28 days post MI ([@B6])
                          Pressure Overload          Dendritic cell ablation following TAC is associated with decreased **IL-1β** and **TGFβ** and less fibrosis ([@B134])
                          Myocarditis/DCM            **BATF3** dependent dendritic cells limit cardiac fibrosis following viral infection ([@B17])
  B and T Cells           Ischemia                   Depletion of **TNFα** T regulatory cells improves fibrosis post MI ([@B12])
                          Pressure Overload          B cell depletion results in decreased fibrosis following TAC ([@B84]) **IFNγ** T cells promote myofibroblast trans differentiation and cardiac fibrosis ([@B98]) CD73 expressing T cells attenuate fibrosis following TAC ([@B110])
                          Myocarditis/DCM            **TNFα** secreting B cells correlate with greater fibrosis in DCM patients ([@B142])

MI, myocardial infarction; CD, cluster of differentiation; Arg-1, arginase 1; GAL3, galectin-3; MPO, myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; NETosis, neutrophil extracellular trap formation; IL-10, interleukin 10; TGFβ, transforming growth factor beta; MCP-1, monocyte chemoattractant protein 1; Gata6, GATA binding protein 6; PDGF, platelet derived growth factor; FGF, fibroblast growth factor; MMP, matrix metallopeptidase; TIMP, tissue inhibitor of metalloproteinases; IL-1β, interleukin 1 beta; TGFβ, transforming growth factor beta; BATF3, basic leucine zipper transcription factor ATF-like 3; IFNγ, interferon gamma; TNFα, tumor necrosis factor alpha.
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Neutrophils {#S3.SS1}
-----------

Neutrophils are polymorphous nuclear leukocytes that are often recognized as the first responders to injury ([@B5]). Neutrophils mature in the bone marrow, and their release is strictly regulated by shifting chemokine gradients; however, it's important to recognize that neutrophils may alter their phenotypes upon exposure to distinct tissue environments ([@B5]; [@B24]). Circulating neutrophils begin injury resolution in the heart by extravasating the activated endothelium, releasing their noxious granular contents, employing their phagocytic capacity, and forming extracellular chromatin traps rich in inflammatory enzymes ([@B5]; [@B53]; [@B87]). The content within neutrophil granules can vary, as they are shaped by the transcriptional program present during formation; however, they typically encompass agents like myeloperoxidase, cathepsins, and neutrophil gelatinase-associated lipocalin (NGAL) which help to repress injury through oxidative and proteolytic actions ([@B5]). Release of neutrophil granules can occur very rapidly after activation, but neutrophil extracellular traps (NETs) are more insidious. NETs result from slow cell death (NETosis) or non-lytic secretions ([@B103]). Essentially, released granular proteases like neutrophil elastase (NE) degrade actin polymers, and disrupt chromatin structure; as neutrophil membranes rupture, these intracellular contents expand to the extracellular space ([@B89]; [@B103]). Altogether, these actions make neutrophils very inflammatory, so consequently, as a benefit to the host, they are very short lived cells ([@B5]).

Neutrophils have gained traction in the field of cardiac fibrosis given their early prevalence in injuries like MI and myocarditis ([@B53]; [@B136]). Following MI, neutrophils invade the heart in response to necrosing tissue, and they accumulate in the infarct border zone ([@B8]; [@B108]). They release inflammatory mediators and proteolytic enzymes in order to assist in clearing dead cells and matrix debris ([@B108]). Neutrophils have mostly been regarded as highly inflammatory cells; earlier studies even suggest that their persistence in sterile inflammation may cause further damage to viable cardiomyocytes ([@B29]; [@B108]). Therefore, recent studies have sought to understand how neutrophil depletion may impact post-MI healing ([@B53]). Interestingly, 1 week following MI, neutralization of neutrophils has been shown to result in worsened cardiac function that is accompanied by enhanced fibroblast activation and excessive collagen deposition ([@B53]). These data suggest that the neutrophil function and secretome may actually be important for mitigating the onset of fibrotic remodeling in a time- and context-dependent manner post-MI. For instance, neutrophils have been shown to persist in post-MI injury due to constant cytokine and DAMP production; these later stage neutrophils function to promote resolution of inflammation ([@B86]). They express archetypal anti-inflammatory genes and release distinct lipid mediators, which are critical in dampening further pro-inflammatory responses ([@B116]; [@B86]; [@B108]). Through gene expression analysis, further studies have provided evidence to support that neutrophils exist along a phenotypic continuum post-MI; they express pro-inflammatory genes early after injury, but participate in ECM reorganization during post-MI repair ([@B86]; [@B20]). Interestingly, the deletion of an enzyme that catalyzes inflammatory metabolites (12/15 lipoxygenase) promotes anti-inflammatory neutrophil phenotypes post-MI, which also correlates with decreased fibroblast activation and collagen deposition by 5 days post-MI injury ([@B64]).

Additional studies have characterized the neutrophil-dependent regulation of fibrosis focusing on other pathological states. For instance, neutrophils have been examined for their contribution to fibrosis and ultimately, atrial fibrillation ([@B39]). After 2 weeks of angiotensin II infusion and deletion of macrophage integrin Mac-1, attenuating the neutrophil infiltration and accumulation within the atrium leads to decreased atrial fibrosis and fibrillation episodes ([@B39]). Recent studies have also focused on how neutrophil processes like NETosis may impact ventricular fibrotic remodeling after injury. Sustained inflammation, even after pathogen clearance makes myocarditis a major risk factor for developing inflammatory dilated cardiomyopathy (DCM) ([@B136]). NETs have been detected in human cases of myocarditis, which can be replicated in mice using experimental models of myocarditis ([@B136]). Following experimental myocarditis, an increase in NETs corresponds to an increase in collagen deposition, which is alleviated upon neutralizing a cytokine essential to neutrophil recruitment and NET formation ([@B136]). The correlation between NETs and fibrosis is further supported in the context of ageing. Ageing is known to trigger the expansion of neutrophils and NETs; disrupting NET formation in aged mice has been shown to improve cardiac function and decrease ageing related interstitial fibrosis ([@B87]). Taken together, neutrophils may serve to regulate fibrosis; however, their actions are clearly context-dependent.

Monocytes and Macrophages {#S3.SS2}
-------------------------

Since their early discovery, we have come to appreciate the complexity of monocyte and macrophage biology. These leukocytes primarily function as key defenders of the innate immune system by sensing for pathogens, digesting debris, and releasing inflammatory mediators ([@B56]). However, years of intense scrutiny has revealed numerous other roles for monocytes and macrophages in organ homeostasis and injury, even in the heart ([@B73]; [@B118]; [@B138]). Macrophages that are innate to the heart stem mainly from embryonic precursors, with some input from circulating monocytes ([@B85]; [@B138]; [@B25]). These resident cardiac macrophages exhibit distinct gene expression profiles, and have the capacity for self-renewal through adulthood ([@B118]; [@B138]). In the case of injury, circulating monocytes infiltrate and differentiate in the heart; these monocyte/macrophage populations have long been evaluated for their contribution in the fibrotic response. Owing to their remarkable plasticity and heterogeneity, monocytes and macrophages have been assessed for their ability to impart both pro- or anti-fibrotic effects in the myocardium ([@B139]). For instance, studies have sought to characterize subsets of monocytes/macrophages which may act as additional cells capable of myofibroblast transdifferentiation. Further, numerous studies have also questioned monocytes/macrophages ability to initiate fibroblast activation or aid in resolution of fibrosis through debris clearance mechanisms ([@B69]). Below, we consider findings of these studies, which suggest subset dependent roles for macrophages and monocytes in cardiac fibrosis.

Until recently, the origin of cardiac myofibroblasts was not entirely clear; however, their induction in response to injury was widely documented ([@B128]). Earlier findings revealed potential roles for leukocytes in heart regeneration post-MI, and posited leukocytes as cell sources of myofibroblast populations in other organs ([@B101]; [@B32]). This led cardiac researchers to hypothesize the same phenomena in the context of ischemic injury. To test the leukocyte contribution to myofibroblast transdifferentiation, studies took advantage of bone marrow transplantation with fluorescent-labeled cells ([@B92]; [@B128]). Following ischemic injury, researchers were able to identify GFP and F4/80 (monocytes/macrophages marker) double positive cells in the infarct, which also co-localized with αSMA ([@B92]; [@B128]). Importantly, the lack of CD31 co-localization suggested these cells were independent of the vasculature ([@B92]). Further analyses of these bone marrow derived myofibroblasts even suggested that they partake in collagen production ([@B128]). Indeed, a recent study using myeloid-specific cre reporter mice (LysM^*Cre/*+^; ROSA26-eYFP) mice has suggested that macrophages can indeed transition toward fibroblast-like cells in the heart following MI with respect to their expression profile of fibroblast markers over time ([@B47]). However, additional genetic lineage tracing studies using similar reporter mice (LysM^*Cre/*+^; Rosa26-eGFP) showed negligible contribution of monocytes and macrophages to myofibroblasts post-MI, which suggest that myofibroblasts derive largely from proliferating and transdifferentiating resident cardiac fibroblasts ([@B66]).

In the injured heart, infiltrating monocytes differentiate into macrophages near spaces rich with collagen producing myofibroblasts; these macrophages can then influence the surrounding cells and ECM through numerous mechanisms ([@B104]; [@B102]). For instance, activated macrophages within the injured myocardium have been shown to contribute to fibroblast activation, proliferation and myofibroblast transformation via secretion of pro-fibrotic factors, including transforming growth factor-beta (TGFβ) and galectin-3 (Gal3) ([@B22]; [@B58]). Additionally, macrophage phagocytosis can often be a trigger in regulating fibrosis ([@B67]), where macrophage ingestion of dead cells and debris leads to the release of pro-fibrotic mediators including TGFβ ([@B93]). However, macrophage phagocytic activity may also contribute to resolution of fibrosis; their ability to take up myofibroblasts and matrix debris may function to reduce the level of fibrotic stimuli ([@B139]; [@B69]). Macrophages also function to secrete inflammatory mediators, which regulate fibroblast activation or ECM remodeling. In detail, activated macrophages can secrete cytokines and factors like interleukin (IL)-1β, tumor necrosis factor α (TNFα), fibroblast growth factor (FGF) and platelet derived growth factor (PDGF) which directly activate fibroblast transdifferentiation, or contribute to increased production of matrix metalloproteinases (MMPs) ([@B63]; [@B69]; [@B102]). Increased production of MMPs leads to excessive matrix remodeling which disrupts fibrotic remodeling ([@B140]; [@B48]; [@B2]). Additional associative studies, particularly focusing on epicardial adipose tissue (EAT) and its role in atrial fibrillation have hinted macrophages involvement in fibrosis ([@B1]). Specifically, an increase in macrophage density in EAT is positively associated with severe EAT fibrosis, which correlates with enhanced atrial fibrosis ([@B1]). Importantly, patients with atrial fibrillation exhibited greater severity of fibrosis ([@B1]). Altogether, these findings provide evidence for the opposing fibrogenic actions of macrophages and its secretome, which suggests the need for careful context dependent analysis when targeting macrophage function in the fibrotic response.

In recent years, much attention has been focused upon tissue resident monocyte/macrophage populations, which function uniquely in the post-injury repair process. For instance, studies have identified distinct peritoneal Gata6 macrophage subsets that are critical for the resolution of inflammation ([@B113]). Gata6 is thought to be essential to these macrophages phenotype, and is key to their ability to self-renew and persist through homeostasis and inflammation ([@B113]). Notably, Gata6 macrophages have been identified in the pericardial cavity of both mice and humans, and they have been shown to regulate cardiac fibrosis following cardiac injury ([@B23]). Four weeks following MI, myeloid-specific deletion of Gata6 resulted in enhanced fibrosis especially in the remote myocardium ([@B23]). These findings suggest the benefits of pericardial macrophages, namely in preventing adverse fibrotic remodeling in viable tissue. Further studies have sought to characterize how resident macrophage subsets influence fibrosis in cardiac injury. For instance, depletion of CCR2^+^ resident macrophages prior to a model of ischemia/reperfusion resulted in decreased fibrosis ([@B10]), while depletion of CX3CR1^+^ resident macrophages led to worsening fibrosis, remodeling and functional outcomes ([@B25]). Considering these findings, it is clear that resident macrophages exert important effects on post-injury cardiac remodeling outcomes, potentially through the regulation of fibrotic responses.

Mast Cells {#S3.SS3}
----------

Mast cells (MC) are most recognized for their function in regulating allergic responses; however, years of thorough investigation has revealed their much more considerable and widespread involvement in the immune system ([@B111]; [@B19]). These secretory leukocytes are characterized by their abundant and diverse granules, which contain a combination of preformed cytokines, growth factors, and proteases ([@B19]). In the absence of injury, MCs reside in low density in tissues like the heart; they originate from bone marrow derived precursors that migrate and subsequently mature into phenotypes dependent on their microenvironments ([@B76]). Injury triggers additional MC precursors to infiltrate the myocardium ([@B99]). For instance, numerous reports have shown increased mast cell counts in DCM patient hearts and animal models of cardiac injury like hypertension and MI ([@B119]; [@B28]; [@B106]; [@B117]; [@B61]). This increase in mast cells following injury has led many researchers to question their involvement in cardiac fibrotic remodeling.

To date, a plethora of compelling results suggest roles for MCs in cardiac fibrosis ([@B75]). For one, in injury, the presence of DAMPs can trigger MC degranulation, which results in the release of inflammatory mediators like tryptase, chymase, IL-1β, and TNFα ([@B75]). Studies have shown that both tryptase and chymase activate TGFβ, a potent fibrogenic mediator known to promote myofibroblast differentiation and collagen production ([@B80]; [@B126]; [@B75]). Similarly, inflammatory cytokines including TNFα have been implicated in the development of cardiac fibrosis during hypertension ([@B88]). MC are also direct sources of fibrogenic mediators. For one, MC have been implicated in atrial fibrosis and fibrillation through enhanced production of the pro-proliferative and fibrotic factor PDGF-A ([@B78]). MC granules have also been shown to contain fibroblast growth factor-2 (FGF2), which has been shown to positively regulate fibroblast proliferation and collagen production ([@B49]; [@B132]; [@B137]). As degranulation products have been shown to induce fibrosis, recent studies have assessed the impact of inhibiting this inflammatory release. Interestingly, treatment with MC stabilizers has been shown to reduce collagen deposition, and collagen gene expression ([@B133]). Further, recent studies focusing on pressure overload induced injury have also identified an association between increasing mast cell volume and fibrosis ([@B83]). These results imply that MCs function to promote adverse fibrotic remodeling; however, arriving at that conclusion may not be accurately reflective. Mice lacking mast cells exhibit only marginally decreased fibrosis 2 weeks after MI ([@B99]). These finding suggest insignificant roles for mast cells in fibrosis, however, interestingly, there is also evidence, which proposes mast cells as anti-fibrotic mediators. Following induction of cardiac dysfunction, mast cell deficient mice show increased perivascular fibrosis ([@B62]). Further, MCs have been shown to produce anti-inflammatory agents including IL-10 which act against fibrosis ([@B79]). Specifically, IL-10 has been repeatedly noted for its ability to oppose fibrosis through reducing collagen gene expression and fibrotic scarring after injury ([@B70]; [@B131]). In sum, the current understanding of the role of mast cells in fibrosis is not entirely clear, which necessitates further studies to address the inconsistencies seen throughout the literature.

Eosinophils {#S3.SS4}
-----------

Eosinophils are a subset of circulating leukocytes that contribute to the clearance of injury primarily through their hydrolase rich granules ([@B115]). Recent focus has been placed on this leukocyte subset as patients exhibiting high levels of eosinophils (eosinophilia) can be at risk for cardiac complications ([@B26]; [@B109]). This clinical phenomenon is supported by recent animal studies that characterize cardiac remodeling in eosinophilia, and see a large response featuring replacement fibrosis ([@B109]). Specifically, mice that develop eosinophilia experience a large influx of eosinophils to the heart, along with enhanced chemokines and cytokines which may function to promote fibrosis ([@B109]). Beyond these findings, additional studies have shown a correlation between enhanced eosinophil accumulation and cardiac fibrosis. Following experimental myocarditis, the depletion of natural killer (NK) cells leads to an accumulation of eosinophils with a concomitant rise in fibrosis ([@B100]). These findings suggest that eosinophils contribute to cardiac fibrosis through cytokine secretion and cellular cross talk; however, more evidence is required in order to understand the exact contribution of eosinophils to cardiac fibrosis. Some studies have begun to address these needs through eosinophil depletion studies. In a model of myocarditis, a lack of eosinophils prevents against the development of inflammatory DCM (DCMi) ([@B26]). While there are no significant changes in total ventricle fibrosis, eosinophil depletion post-myocarditis leads to decreased expression of MMP2 and tissue inhibitor of metalloproteinases 2 (TIMP2) ([@B26]). These reports highlight the need for definitive assessment of the mechanisms by which eosinophils may trigger cardiac fibrosis.

Dendritic Cells {#S3.SS5}
---------------

Dendritic cells (DC) are key immune regulators that function to initiate adaptive responses through antigen processing and presentation ([@B27]). They can be characterized as being classical or non-classical, both of which exist in numerous subsets ([@B90]). DCs are highly abundant in barrier tissues like the skin, however, many reports have shown their presence in heart tissue ([@B129]). Specifically, recent studies have suggested at least two types of classical or conventional DCs (cDC) in the healthy heart ([@B130]). These cDCs have been shown to mediate tolerance to self-antigens ([@B130]). DCs become of even greater relevance as the heart experiences injury ([@B17]; [@B130]; [@B134]). Their specific roles in pathology, especially in relation to cardiac fibrosis, is distinct; we consider them below.

A few studies have highlighted an influx of CD11c^+^ cDCs to the heart following ischemic injury that increase starting 1 day post-MI that peak around 5--7 days post-MI ([@B6]; [@B130]). This early rise in DCs has led researchers to hypothesize additional roles for DCs in repair and remodeling post-injury. Accordingly, models of CD11c^+^ depletion have been applied, and following MI, a lack of bone marrow derived CD11c^+^ cells results in decreased survival rates and significantly enhanced fibrosis ([@B6]). Although this model relies on the non-specific loss of all CD11c^+^ cells, these findings provided evidence for DCs as being somewhat protective after infarction. Interestingly, this protective DC theory can be further supported by studies analyzing DC densities in humans post-MI or in DCM ([@B107]; [@B94]). For instance, patients with DCM have decreased DCs compared to controls, and experience enhanced fibrosis and worsened cardiac function ([@B107]). There are also additional studies, focused on myocarditis, which suggest protective DC roles following injury ([@B17]). A specific deletion of cardiac CD103^+^ DCs results in significantly enhanced fibrosis following viral myocarditis, which suggests the role of DCs in blunting the transition to HF following injury ([@B17]).

Beyond these findings, however, it is also important to note the wealth of literature that hints at an opposing role for DCs following injury. With CD11c^+^ cell depletion, 24 weeks after TAC, mice exhibit reduced LV fibrosis and decreased expression of fibroblast activating genes ([@B134]). These studies are met with similar critiques regarding lack of DC specificity, however, studies using a more specific model of cDC ablation also show decreased LV fibrosis 3 weeks post-MI ([@B74]). These findings are further supported by earlier studies which show cardiac and splenic DC activation and expansion 8 weeks post-MI ([@B59]). Interestingly, transfer of splenocytes from these HF mice into naïve mice results in the development of HF accompanied with significant fibrosis ([@B59]). Taken together, these studies provide evidence for DCs in post-injury remodeling, however, there is limited insight into how DCs may influence fibrosis. Overall, consideration of findings from each of these studies suggests a continued need for further DC characterization in the heart, focusing on how unique and specific populations of DCs may act to govern the fibrotic response.

B and T -- Lymphocytes {#S3.SS6}
----------------------

An abundance of literature suggests an involvement of both B and T-- Lymphocytes (B and T cells) in cardiac fibrosis. These adaptive immune cells are found in small numbers in the steady state heart, but are known to rise post-injury ([@B143]; [@B135]). The functional relevance of these lymphocytes in the steady state heart is still becoming understood, however, following injury, several reports have documented their ability to influence long-term remodeling outcomes ([@B142]; [@B143]; [@B52]). For instance, B cells have been shown to be associated with enhanced fibrosis; their depletion results in reduced collagen deposition following TAC, MI, and the development of non-ischemic cardiomyopathy ([@B18]; [@B52]; [@B84]). B cells are thought to promote fibrosis through inflammatory cytokines like IL-1β, IL6, and TNFα, all of which have been linked to increased fibrosis ([@B18]). Interestingly, these findings are supported by other studies that identify increased B cell densities and cardiac fibrosis in DCM patients when compared to healthy controls ([@B142]). B cells isolated from these DCM patients secrete larger quantities of pro-fibrotic factors including TNFα; these findings provide additional evidence to support the pro-fibrotic actions of B cells in injury ([@B142]). In moving forward, much remains to be understood in the field of cardiac B cell biology, including the explicit role that B cells play in the uninjured heart, as well as the mechanisms by which they elicit pathological fibrotic remodeling.

Similar to B cells, T cells have been shown to infiltrate the injured myocardium where they greatly influence remodeling outcomes ([@B13]). T cells come in many subsets, some of which have divergent functions in cardiac fibrosis. For one, CD4^+^ T cells accumulate in the heart post-MI and -TAC, and are associated with enhanced cardiac fibrosis ([@B72]; [@B97], [@B98]; [@B11], [@B12]; [@B14]; [@B110]). Studies have shown increased Th1 polarization following injury, leading to the production of pro-inflammatory and -fibrotic cytokines like interferon γ (IFNγ) ([@B72]; [@B98]). As these subsets of T cells are implicated in worsening fibrosis, many reports have sought to characterize their direct involvement in the remodeling response. The depletion or dampening of T cell infiltration post-injury has been shown to result in a significant reduction of fibrosis and fibrosis associated gene expression ([@B72]; [@B97]; [@B114]). Recent studies have also shown a direct increase in cardiac fibrosis following adoptive transfer of HF splenic CD4^+^ T cells into naïve mice ([@B11]). Mechanistically, a few targets have been investigated in their role for inducing pro-fibrotic T cell actions. Namely, studies have determined an involvement of CD73 and adenosine generation, as T cell-specific CD73 knockout mice show enhanced fibrosis ([@B14]; [@B110]). These studies suggest that adenosine functions in an autocrine manner to reduce the production of pro- inflammatory and -fibrotic cytokines ([@B14]). Further, signaling through the mineralocorticoid receptor (MR) has been shown to enhance pro-fibrotic T cell actions, as the loss of T cell MR has been shown to decrease T cell activation and fibrotic cytokine production ([@B77]). Interestingly, all of these findings seem to be associated with CD4^+^ T cells, as similar assessments have revealed no significant role for CD8^+^ T cells in cardiac fibrosis ([@B45]).

Studies have also examined the role of T regulatory (Treg) subsets in fibrosis, and have mainly shown their role in protecting against fibrosis ([@B71]; [@B65]; [@B125]). Early studies have shown decreased collagen content and lower expression of pro-fibrotic mediators following Treg introduction into hypertensive injury models ([@B71]; [@B65]). Additionally, the introduction of Tregs post-MI has also been shown to reduce border zone fibrosis, further suggesting a protective mechanism through which Tregs influence remodeling ([@B125]). However, recent studies have shown alternative Treg functions post-injury, wherein an increase in a pro-inflammatory CD4^+^ Treg subset has been shown to lead to the production of fibrotic cytokines like TNFα ([@B12]). Additional studies directed toward the characterization of the impact of specific T cell subsets on cardiac fibrosis at distinct timepoints after injury will be helpful to illuminate potential targets against pathological cardiac fibrosis.

Concluding Remarks {#S4}
==================

Fibrotic remodeling is a normal physiological response to injury in the heart, however, when it becomes excessive, fibrosis leaves the heart at a great detriment in that it leads to tissue stiffness and dysfunction ([@B50]). As such, the prevention or reversal of pathological fibrotic remodeling has been a research target for numerous years and has led to a wealth of studies aimed in uncovering the mechanistic basis for cardiac fibrosis. Recently, studies using isolated myofibroblasts from HF patients have suggested the possibility of reversing fibrosis by inhibition of TGFβ receptor signaling ([@B36]; [@B95]). These findings provide support to reason the idea of myofibroblasts returning to quiescent fibroblast states ([@B95]). However, translating these findings *in vivo* will require consideration of numerous other factors which influence cardiac fibrosis. For one, several leukocyte subsets are implicated in the development of fibrosis. Currently, their explicit contribution to cardiac fibrosis, which appears context-dependent, is still being unraveled, as is the practicality of targeting specific subtypes at particular phases of post-injury remodeling of HF development. For instance, the presence of dendritic cells may be beneficial toward stable scar formation in MI patients, however, their exact role in the regulation of fibrotic remodeling and how to support their activity will need to be understood to effectively translate this knowledge toward therapeutic application ([@B94]). Further, patients with non-ischemic HF have been shown to exhibit higher numbers of activated CD3^+^ T cells; given the number of animal studies showcasing their association with fibrosis, antagonizing these lymphocytes could serve as a feasible therapeutic avenue against pathological fibrosis during HF ([@B97]). To conclude, a growing body of evidence suggests multifaceted roles for leukocytes in cardiac injury: both innate and adaptive leukocytes influence pathological fibrotic remodeling, presenting an exciting trajectory for the development of novel therapeutic strategies that modulate their recruitment, secretions and phenotypes to prevent the progression of both ischemic and non-ischemic forms of HF.
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